Brief: Rovi Sees 2024 Operating Revenue To Decrease By Mid-Single-Digit Percentage Vs 2023

Laboratorios Farmaceuticos Rovi

07/11/2024 06:52

Nov 7 (Reuters) - Laboratorios Farmaceuticos ROVI SA
 ROVI.MC :
    * EXPECTS 2024 OPERATING REVENUE TO DECREASE BY
MID-SINGLE-DIGIT
PERCENTAGE VERSUS 2023
    * SEES 2025 OPERATING REVENUE TO DECREASE BY A
MID-SINGLE-DIGIT
PERCENTAGE VERSUS 2024
    * RISVAN TO NOT BE MARKETED IN THE U.S.

Source text for Workspace:  ID:nCNM1sG42D 
Further company coverage:  ROVI.MC 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))